当前位置: 首页 > 期刊 > 《中国医学创新》 > 2021年第5期
编号:186408
痛风继发阻塞性睡眠呼吸暂停综合征患者潜在发病机制及生物标记、亚型的研究进展
http://www.100md.com 2021年5月8日 中国医学创新 2021年第5期
     陈建春 周攀 谭巍 郑武燕

    【摘要】 近年来,已有针对痛风继发阻塞性睡眠呼吸暂停综合征(obstructive sleep apnea,OSA)患者的诊断、发病率的调查研究,显示痛风与OSA具有相关性,但二者共同发病的危险因素、关联程度和发展机制尚不清楚。临床若对这两种疾病进行单独治疗,用药种类会增多,药物产生副作用的风险增加,造成临床治疗效果不佳。提示临床治疗痛风合并OSA患者应综合考虑制定合理治疗策略。另外,最新的研究发现对痛风合并OSA患者调查不连贯性和不均一性,可将此类患者分为不同的亚型进行调查。本文对痛风合并OSA疾病发生和发展机制、亚型的最新研究进展进行综述。

    【关键词】 痛风 阻塞性睡眠呼吸暂停综合征 发病机制 生物标记

    Research Progress on Potential Pathogenesis and Biomarker Subtypes of Patients with Obstructive Sleep Apnea Syndrome Secondary to Gout/CHEN Jianchun, ZHOU Pan, TAN Wei, ZHENG Wuyan. //Medical Innovation of China, 2021, 18(05): -184

    [Abstract] In recent years, there have been studies on the diagnosis and incidence of patients with obstructive sleep apnea (OSA) secondary to gout, showing that gout has a correlation with OSA. However, the risk factors, the degree of association and the mechanism of development of the two common diseases are still unclear. If these two diseases are treated separately in clinical practice, the types of drugs will increase, and the risk of side effects of drugs will increase, resulting in poor clinical treatment effect. It is suggested that the clinical treatment of patients with gout combined with OSA should take comprehensive consideration to develop reasonable treatment strategy. In addition ......

您现在查看是摘要页,全文长 16128 字符